Eden Biodesign to offer Millipore’s Expression Technology as part of its Cell Line Development Services
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
Eden Biodesign Ltd. and Millipore Corporation announced a partnership that will provide biopharmaceutical companies with access to a powerful combination of Eden’s cGMP manufacturing and Millipore’s Ubiquitous Chromatin Opening Elements (UCOE®) expression technology.
“We are pleased to collaborate with Eden Biodesign in the complex mammalian cell development arena and have high expectations for the ongoing success of this partnership.”
As part of this agreement, Eden Biodesign will employ Millipore’s proprietary UCOE® expression technology to undertake mammalian cell line development projects and cGMP production for third-party clients.
Millipore’s UCOE® technology provides major improvements in gene expression for stably transfected mammalian cells through effects on the structure of chromatin. Cells developed using Millipore’s UCOE® technology are stable high-expressors, which means it is easier and faster for biopharmaceutical manufacturers to identify high-yielding clones with the productivity and stability required for biomanufacturing than with many other expression systems.
“We are delighted to work with a recognized industry leader like Millipore to make this extremely valuable technology available to our clients around the world,” said Roger Lias, Ph.D., president of Eden Biodesign’s North American subsidiary. “Speed-to-clinic and the ability to rapidly develop highly productive cell lines that will support economically viable production through clinical development, process scale-up and steady-state large scale commercial supply are vitally important considerations for our clients.”
“We are pleased to collaborate with Eden Biodesign in the complex mammalian cell development arena and have high expectations for the ongoing success of this partnership.”
As part of this agreement, Eden Biodesign will employ Millipore’s proprietary UCOE® expression technology to undertake mammalian cell line development projects and cGMP production for third-party clients.
Millipore’s UCOE® technology provides major improvements in gene expression for stably transfected mammalian cells through effects on the structure of chromatin. Cells developed using Millipore’s UCOE® technology are stable high-expressors, which means it is easier and faster for biopharmaceutical manufacturers to identify high-yielding clones with the productivity and stability required for biomanufacturing than with many other expression systems.
“We are delighted to work with a recognized industry leader like Millipore to make this extremely valuable technology available to our clients around the world,” said Roger Lias, Ph.D., president of Eden Biodesign’s North American subsidiary. “Speed-to-clinic and the ability to rapidly develop highly productive cell lines that will support economically viable production through clinical development, process scale-up and steady-state large scale commercial supply are vitally important considerations for our clients.”
